Ginkgo & OpenAI Slash Protein Synthesis Costs by 40%
Ginkgo Bioworks teams up with OpenAI to cut cell-free protein synthesis costs by 40% using AI and cloud lab automation.
Already have an account? Sign in.
Ginkgo Bioworks teams up with OpenAI to cut cell-free protein synthesis costs by 40% using AI and cloud lab automation.
Software stocks (IGV) dropped 4.3% after Amazon revealed it’s building AI agents to automate sales, cybersecurity and networking jobs.
Grifols has approved a U.S. IPO of a minority stake in its Biopharma business.
Gilead’s up to $2.2B acquisition of Ouro Medicines highlights strong potential for Cullinan Therapeutics’ velinotamig. Clear Street maintains Buy rating with $33 PT.